摘要
目的:探讨氯吡格雷在冠状动脉介入治疗中的有效性和安全性。方法:回顾性分析174例接受药物洗脱支架(DES)植入患者的临床资料。结果:氯吡格雷600、900mg组血小板聚集率(PA)抑制明显,发生氯吡格雷抵抗病例少,临床心血管事件发生少;主要出血事件各组之间无明显差别。结论:600、900mg组抑制PA效果更明显、临床心血管事件发生更少,600mg负荷剂量优势更明显。
Objective:To investigate the efficacy and safety of Clopidogreal in percutaneous coronary intervention.Methods:The clinical data of 174 patients received drug-eluting stent (DES) implantation were retrospectively analyzed.Results:The time to the peak value of PA inhibition was lower in 600 mg and 900 mg groups than that in the other groups,the Clopidogrel resistance was also lower in 600 mg and 900 mg groups,the clinical cardiovascular event in 600,900 mg group was lower than the conventional loading dosage group.Safety end points were similar in the 3 groups.Conclusion:Pretreatment with 600,900 mg loading dosage of Clopidogrel 6 to 24 hours before the procedure can significantly reduce PA and maintain for a longer time with less occurrence of clinical cardiovascular event,the 600 mg may be the best.
出处
《中国医药导报》
CAS
2010年第23期84-85,共2页
China Medical Herald
关键词
氯吡格雷
负荷剂量
冠状动脉介入术
药物涂层支架
Clopidogrel
Loading dose
Percutaneous coronary intervention
Drug-eluting stent
